Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance

Only a subset of cancer patients respond to T-cell checkpoint inhibitors, highlighting the need for alternative immunotherapeutics. We performed CRISPR-Cas9 screens in a leukemia cell line to identify perturbations that enhance natural killer effector functions. Our screens defined critical components of the tumor-immune synapse and highlighted the importance of cancer cell interferon-g signaling in modulating NK activity. Surprisingly, disrupting the ubiquitin ligase substrate adaptor DCAF15 strongly sensitized cancer cells to NK-mediated clearance. DCAF15 disruption induced an inflamed state in leukemic cells, including increased expression of lymphocyte costimulatory molecules. Proteomic and biochemical analysis revealed that cohesin complex members were endogenous client substrates of DCAF15. Genetic disruption of DCAF15 was phenocopied by treatment with indisulam, an anticancer drug that functions through DCAF15 engagement. In AML patients, reduced DCAF15 expression was associated with improved survival. These findings suggest that DCAF15 inhibition may have useful immunomodulatory properties in the treatment of myeloid neoplasms.

[1]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[2]  R. Wysocki,et al.  The Emerging Role of Cohesin in the DNA Damage Response , 2018, Genes.

[3]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[4]  D. Jackson,et al.  MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma , 2018, Science Translational Medicine.

[5]  T. Owa,et al.  Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome , 2018, Cancer.

[6]  K. Brown,et al.  Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.

[7]  P. Gonzalez-Ericsson,et al.  Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 , 2018, Oncoimmunology.

[8]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[9]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[10]  Michael P Weekes,et al.  Compositional Proteomics: Effects of Spatial Constraints on Protein Quantification Utilizing Isobaric Tags , 2017, Journal of proteome research.

[11]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[12]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[13]  Hamid Bolouri,et al.  The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions , 2017, Nature Medicine.

[14]  L. Galluzzi,et al.  Control of Metastasis by NK Cells. , 2017, Cancer cell.

[15]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[16]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[17]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[18]  Margaret A. Goralski,et al.  Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 , 2017, Science.

[19]  T. Owa,et al.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides. , 2017, Nature chemical biology.

[20]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[21]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[22]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[23]  A. Cerwenka,et al.  CD2–CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection , 2016, European journal of immunology.

[24]  A. May,et al.  DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks. , 2016, Molecular cell.

[25]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[26]  Lior Pachter,et al.  Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.

[27]  F. Uhlmann.  SMC complexes: from DNA to chromosomes , 2016, Nature Reviews Molecular Cell Biology.

[28]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[29]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[30]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[31]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[32]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[33]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[34]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[35]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[36]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[37]  Luke A. Gilbert,et al.  Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2013, Cell.

[38]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[39]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[40]  Brian Burke,et al.  A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells , 2012, The Journal of cell biology.

[41]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[42]  S. Gygi,et al.  MS3 eliminates ratio distortion in isobaric labeling-based multiplexed quantitative proteomics , 2011, Nature Methods.

[43]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[44]  J. Schatzle,et al.  Cutting Edge: The Adapters EAT-2A and -2B Are Positive Regulators of CD244- and CD84-Dependent NK Cell Functions in the C57BL/6 Mouse , 2010, The Journal of Immunology.

[45]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[46]  Yue Xiong,et al.  CRL4s: the CUL4-RING E3 ubiquitin ligases. , 2009, Trends in biochemical sciences.

[47]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[48]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[49]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[50]  J. Harper,et al.  Ubiquitin proteasome system (UPS): what can chromatin do for you? , 2007, Current opinion in cell biology.

[51]  J. Chen,et al.  A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. , 2006, Molecular cell.

[52]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[53]  C. Münz,et al.  NK Cell Compartments and Their Activation by Dendritic Cells1 , 2004, The Journal of Immunology.

[54]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[55]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[56]  U. Scherf,et al.  Induced Dendritic Cell Differentiation of Chronic Myeloid Leukemia Blasts Is Associated with Down-Regulation of BCR-ABL1 , 2003, The Journal of Immunology.

[57]  A. Janulaitis,et al.  AarI, a restriction endonuclease from Arthrobacter aurescens SS2-322, which recognizes the novel non-palindromic sequence 5'-CACCTGC(N)4/8-3'. , 2002, Nucleic acids research.

[58]  Pablo Engel,et al.  CD84 Functions as a Homophilic Adhesion Molecule and Enhances IFN-γ Secretion: Adhesion Is Mediated by Ig-Like Domain 11 , 2001, The Journal of Immunology.

[59]  Ying K. Tam,et al.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. , 2001, Journal of hematotherapy & stem cell research.

[60]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[61]  M T Bejarano,et al.  NK cell triggering by the human costimulatory molecules CD80 and CD86. , 1999, Journal of immunology.

[62]  F. Farzaneh,et al.  Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. , 1999, Journal of immunology.

[63]  H. Ljunggren,et al.  Triggering of murine NK cells by CD40 and CD86 (B7-2). , 1999, Journal of immunology.

[64]  H. Ljunggren,et al.  Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1) , 1996, Immunity.

[65]  Jürgen Bajorath,et al.  Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28 (*) , 1995, The Journal of Biological Chemistry.

[66]  D. Horsman,et al.  Establishment and characterization of a human leukemic cell line (SR-91) with features suggestive of early hematopoietic progenitor cell origin. , 1994, Leukemia & lymphoma.

[67]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[68]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[69]  L. Lanier,et al.  Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. , 1992, Journal of immunology.

[70]  Michael Loran Dustin,et al.  The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3 , 1987, Nature.

[71]  R. Karr,et al.  Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation , 1986, Molecular and cellular biology.

[72]  R. Majeti,et al.  The role of mutations in the cohesin complex in acute myeloid leukemia , 2016, International Journal of Hematology.

[73]  W. Haas,et al.  Multiplexed Quantitative Proteomics for High-Throughput Comprehensive Proteome Comparisons of Human Cell Lines. , 2016, Methods in molecular biology.

[74]  Benjamin G. Gowen,et al.  Recognition of tumors by the innate immune system and natural killer cells. , 2014, Advances in immunology.

[75]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[76]  A. Veillette.  Immune regulation by SLAM family receptors and SAP-related adaptors , 2006, Nature Reviews Immunology.